Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2014 Mar;21(3):260-6.
doi: 10.1097/GME.0b013e31829a64f9.

Hormone therapy dose, formulation, route of delivery, and risk of cardiovascular events in women: findings from the Women's Health Initiative Observational Study

Chrisandra L Shufelt  1 , C Noel Bairey Merz, Ross L Prentice, Mary B Pettinger, Jacques E Rossouw, Vanita R Aroda, Andrew M Kaunitz, Kamakshi Lakshminarayan, Lisa W Martin, Lawrence S Phillips, Joann E Manson
Affiliations
Comparative Study

Hormone therapy dose, formulation, route of delivery, and risk of cardiovascular events in women: findings from the Women's Health Initiative Observational Study

Chrisandra L Shufelt et al. Menopause. 2014 Mar.

Abstract

Objective: Research comparing hormone therapy (HT) doses, regimens, and routes of delivery in relation to cardiovascular disease (CVD) outcomes has been limited. This study directly compared different estrogen doses, routes of delivery, and HT formulations in postmenopausal women in relation to the risk of coronary heart disease (CHD), stroke, CVD mortality, total CVD, and all-cause mortality.

Methods: The Women's Health Initiative Observational Study is a multicenter prospective cohort study that was conducted at 40 US sites. Analyses included 93,676 postmenopausal women aged 50 to 79 years at study entry who were recruited from September 1994 to December 1998, with annual follow-up through August 14, 2009.

Results: The mean follow-up was 10.4 years. In direct comparisons, oral estradiol was associated with lower hazard ratios (HRs) for stroke than oral conjugated equine estrogens (CEE; HR, 0.64; 95% CI, 0.40-1.02), but statistical power was limited. Similarly, transdermal estradiol was associated with a moderate but nonsignificantly lower risk of CHD compared with oral CEE (HR, 0.63; 95% CI, 0.37-1.06). For other outcomes, comparisons revealed no appreciable differences by estrogen doses, formulations, or routes of delivery. Absolute risks of CVD events and all-cause mortality were markedly lower in younger women compared with older women.

Conclusions: In direct comparisons, various HT doses and regimens are associated with similar rates of cardiovascular events and all-cause mortality. However, oral estradiol may be associated with a lower risk of stroke, and transdermal estradiol may be associated with a lower risk of CHD, compared with conventional-dose oral CEE. Additional research is needed to confirm these hypotheses.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Absolute Risk among women using Conventional dose CEE with or without Progestin/progesterone: Cases per 10,000 person-years during the first 5 years of follow-up
See this image and copyright information in PMC

Comment in

Similar articles

See all similar articles

Cited by

  • Brazilian Guideline on Menopausal Cardiovascular Health - 2024.
    de Oliveira GMM, de Almeida MCC, Arcelus CMA, Espíndola L, Rivera MAM, da Silva-Filho AL, Marques-Santos C, Fernandes CE, Albuquerque CJDM, Freire CMV, Izar MCO, Costa MENC, de Castro ML, Lemke VMG, de Lucena AJG, Brandão AA, Macedo AVS, Polanczyk CA, Lantieri CJB, Nahas EP, Alexandre ERG, Campana EMG, Bragança ÉOV, Colombo FMC, Barbosa ICQ, Rivera IR, Kulak J, Moura LAZ, Pompei LM, Baccaro LFC, Barbosa MM, Rodrigues MAH, Albernaz MA, de Decoud MSP, Paiva MSMO, Sanchez-Zambrano MB, Campos MDSB, Acevedo M, Ramirez MS, de Souza OF, de Medeiros OO, de Carvalho RCM, Machado RB, da Silva SCTF, Rodrigues TCV, Avila WS, da Costa-Paiva LHS, Wender MCO. de Oliveira GMM, et al. Rev Bras Ginecol Obstet. 2024 Oct 15;46:e-rbgo100. doi: 10.61622/rbgo/2024rbgo100. eCollection 2024. Rev Bras Ginecol Obstet. 2024. PMID: 39530071 Free PMC article. No abstract available.
  • Brazilian Guideline on Menopausal Cardiovascular Health - 2024.
    Oliveira GMM, Almeida MCC, Arcelus CMA, Neto Espíndola L, Rivera MAM, Silva-Filho ALD, Marques-Santos C, Fernandes CE, Albuquerque CJDM, Freire CMV, Izar MCO, Costa MENC, Castro ML, Lemke VMG, Lucena AJG, Brandão AA, Macedo AVS, Polanczyk CA, Lantieri CJB, Nahas EP, Alexandre ERG, Campana EMG, Bragança ÉOV, Colombo FMC, Barbosa ICQ, Rivera IR, Kulak J, Moura LAZ, Pompei LM, Baccaro LFC, Barbosa MM, Rodrigues MAH, Albernaz MA, Decoud MSP, Paiva MSMO, Sanchez-Zambrano MB, Campos MDSB, Acevedo M, Ramirez MS, Souza OF, Medeiros OO, Carvalho RCM, Machado RB, Silva SCTFD, Rodrigues TCV, Avila WS, Costa-Paiva LHSD, Wender MCO. Oliveira GMM, et al. Arq Bras Cardiol. 2024 Aug 16;121(7):e20240478. doi: 10.36660/abc.20240478. Arq Bras Cardiol. 2024. PMID: 39166619 Free PMC article. English, Portuguese. No abstract available.
  • The impact of female sex hormones on cardiovascular disease: from mechanisms to hormone therapy.
    Kan Y, Peng YL, Zhao ZH, Dong ST, Xu YX, Ma XT, Liu XL, Liu YY, Zhou YJ. Kan Y, et al. J Geriatr Cardiol. 2024 Jun 28;21(6):669-681. doi: 10.26599/1671-5411.2024.06.003. J Geriatr Cardiol. 2024. PMID: 38973823 Free PMC article.
  • The Relationship Between Myocardial Infarction and Estrogen Use: A Literature Review.
    Javed A, Ravi PC, Bilal Delvi S, Faraz Hussain I, Acosta G AJ, Iqbal W, Krishnamaneni V, Alasaadi S, Pradhan S, Vashisht R, Modi S. Javed A, et al. Cureus. 2023 Sep 28;15(9):e46134. doi: 10.7759/cureus.46134. eCollection 2023 Sep. Cureus. 2023. PMID: 37900417 Free PMC article. Review.
  • The menopausal transition period and cardiovascular risk.
    Mehta JM, Manson JE. Mehta JM, et al. Nat Rev Cardiol. 2024 Mar;21(3):203-211. doi: 10.1038/s41569-023-00926-7. Epub 2023 Sep 26. Nat Rev Cardiol. 2024. PMID: 37752349 Review.
See all "Cited by" articles

References

    1. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial. JAMA. 2002 Jul 17;288(3):321–333. - PubMed
    1. Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial. JAMA. 2004 Apr 14;291(14):1701–1712. - PubMed
    1. Estrogen and progestogen use in postmenopausal women: 2010 position statement of The North American Menopause Society. Menopause. 2010;17(2):242–255. 210.1097/gme.1090b1013e3181d1090f1096b1099. - PubMed
    1. ACOG Committee Opinion No. 420, November 2008: hormone therapy and heart disease. Obstet Gynecol. 2008 Nov;112(5):1189–1192. - PubMed
    1. Santen RJ, Allred DC, Ardoin SP, et al. Postmenopausal hormone therapy: an Endocrine Society scientific statement. J Clin Endocrinol Metab. 2010 Jul;95(7 Suppl 1):s1–s66. - PMC - PubMed

Publication types

MeSH terms